Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

157 results
Display

Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates

Piao XM, Kang H, Kim WJ, Yun SJ

Molecular markers detected in urine may improve our understanding of the evolution of bladder cancer (BCa) and its micro- and macroenvironment. Detection of such markers will identify disease earlier, allow...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Stratifying risk for multiple, recurrent, and large (≥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer

Suh J, Jung JH, Kwak C, Kim HH, Ku JH

Purpose: The current stratification of risk groups regarding recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) is problematic. We aimed to assess the long-term outcome and risk of multiple, recurrent,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patterns of Locoregional Recurrence after Radical Cystectomy for Stage T3-4 Bladder Cancer: A Radiation Oncologist’s Point of View

Kim HJ, Chun J, Kim TH, Yang G, Shin SJ, Kim JS, Yang J, Ham WS, Koom WS

Purpose: Adjuvant radiotherapy (RT) has been performed to reduce locoregional failure (LRF) following radical cystectomy for locally advanced bladder cancer; however, its efficacy has not been well established. We analyzed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Emerging treatments for bacillus Calmette– Guérin-unresponsive non-muscle-invasive bladder cancer

Kim HS, Seo HK

Intravesical bacillus Calmette–Guérin (BCG) immunotherapy has been the gold standard adjuvant treatment for intermediateand high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). BCG immunotherapy prevents disease...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment of advanced urogenital cancers with immune checkpoint inhibitors

Jung EH, Kim SH

The development of immune checkpoint inhibitors has improved the long-term survival of patients with several types of cancers, including bladder and renal cell carcinomas. Atezolizumab, an anti-programmed death-ligand 1 monoclonal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Perioperative Outcomes of Different Surgical Methods Among Bladder Cancer Patients Undergoing Radical Cystectomy With Neobladder Urinary Diversion

Kim HJ, Ye C, Kim JH, Kim H, Lee S, Byun SS, Oh JJ

Purpose: To compare perioperative outcomes according to surgical methods among bladder cancer patients who underwent radical cystectomy (RC) with neobladder urinary diversion. Materials and Methods: Between June 2007 and January 2020,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review

Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P

Purpose: To assess the comparative effectiveness and toxicity of intravesical gemcitabine instillation for non-muscle invasive bladder cancer (NMIBC). Materials and Methods: We performed a comprehensive literature search on 11 September 2020....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Approaches for Personalized Drug Development in Bladder Cancer Patients

Seol HS, Chang IH

Bladder cancer, which affects the bladder mucosa, is the ninth most common disease worldwide. There are manytypes of cancerous tissue in the bladder. Most exhibit low malignancy, but their recurrence...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Therapeutic Options in High-Risk Nonmuscle Invasive Bladder Cancer During the Shortage of Bacillus Calmette-Guérin

Yoo J, Kim YJ, Tae BS, Park JY

Bladder cancer is the second most common malignant tumor of the urinary tract and is the seventh most commoncancer among men worldwide and 17th among women. Seventy to eighty percent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer

Carvalho FL, Zeymo A, Egan J, Kelly CH, Zheng C, Lynch JH, Hwang J, Stamatakis L, Krasnow RE, Kowalczyk KJ

Purpose: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard of care for muscleinvasive bladder cancer (MIBC). However, NAC is used in less than 20% of patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association between perioperative glucocorticoids and cancer metastasis and survival in patients undergoing radical cystectomy for urothelial carcinoma of the bladder: A singlecenter retrospective study

Mao S, Wu Y, Wang R, Guo Y, Yuan J, Zhang W, Zhang J, Yan Y, Yao X

Purpose: Perioperative glucocorticoids have the potential to increase the risk of tumor metastasis. However, the relationship between perioperative glucocorticoids and oncologic outcomes remains controversial. The present study was undertaken to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review

Schmidt S, Kunath F, Coles B, Draeger DL, Krabbe LM, Dersch R, Kilian S, Jensen K, Dahm P, Meerpohl JJ

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The effect of atropine in preventing catheter-related pain and discomfort in patients undergoing transurethral resection due to bladder tumor; prospective randomized, controlled study

Şahiner Y, Yağan , Ekici AA, Ekici M, Demir E

Background: Catheter-related bladder discomfort (CRBD) has been observed in many patients undergoing a urethral catheterization. CRBD may be so severe that the patients require additional analgesics. Muscarinic receptors are involved...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Developing Biomarkers and New Therapeutic Targets in Muscle Invasive Bladder Cancer

Ha YS

Muscle-invasive bladder cancer (MIBC) is classified into a heterogeneous life-threatening epithelial tumor with a high rate of metastasis and a dismal survival rate. Dissimilarity in genetic or epigenetic environment of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Von Brunn’s Nest in an Incidental Bladder Mass Found during Holmium Laser Enucleation of the Prostate

Lee S

A 62-year-old male with benign prostatic hyperplasia underwent holmium laser enucleation of the prostate. During surgery, a small nodular mass was found incidentally in the trigone of the bladder. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects

Shahid M, Kim M, Yeon A, Jin P, Kim WK, You S, Kim J

Purpose: Pioglitazone, an antihyperglycemic drug, is widely used in diabetes mellitus patients with insulin resistance. Although pioglitazone is known to have a potential link to bladder cancer (BC), there have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Advances in urinary biomarker discovery in urological research

Kim J, Kim WT, Kim WJ

A disease-specific biomarker (or biomarkers) is a characteristic reflecting a pathological condition in human body, which can be used as a diagnostic or prognostic tool for the clinical management. A...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Postoperative Recurrent Bladder Tumors Detection by Narrow-Band Imaging Cystoscopy

Seo WT, Kang SH

Purpose: We compared the effectiveness of narrow-band imaging (NBI) cystoscopy and white light cystoscopy (WLC) for detection of intravesical recurrence of bladder cancer. Materials and Methods: We studied the positive predictive...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy Followed by Radical Cystectomy: A Single-Center Retrospective Study

Cho JH, Kwon GY, Kang M, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Lee SJ, Park SH

Purpose: There remains a lot of unmet need to increase understanding of node-positive (ypN+) muscle invasive bladder cancer (MIBC) after neoadjuvant chemotherapy and radical cystectomy to decide the appropriate therapeutics. Materials...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Urinary Biomarker in Bladder Cancer at Present Time

Kim SH, Lee HH, Seo HK

Current standard diagnostic modality of bladder cancer is cystoscopy with/without urine cytology from patient’s voided urine. Considering several cystoscopic disadvantages such as symptomatic invasiveness and operatordependency, urinary cytology is an...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr